Case Report

Acrual Lentiginous Melanoma: A Case Control Study and Guidelines Update

Christoforos Kosmidis,1 Christoforos Efthimiadis,1 Georgios Anthimidis,1 Marios Grgioriou,1 Kalliopi Vasiliadou,1 Georgia Ioannidou,2 Fotini Makedou,3 and Sofia Baka3

1 Department of Surgery, Interbalkan European Medical Center, 84 Tsimiski Street, 54622 Thessaloniki, Greece
2 Department of Radiology, “Panagia” General Hospital, 22 Nik. Plastira street, Nea Krini, Kalamaria, 55132 Thessaloniki, Greece
3 Department of Oncology, Interbalkan European Medical Center, 10 Asklipiou street, Pylaia, 57001 Thessaloniki, Greece

Correspondence should be addressed to Christoforos Kosmidis, dr.ckosmidis@gmail.com

Received 11 October 2010; Accepted 15 February 2011

1. Introduction

The incidence of malignant melanoma is rising at a rate faster than any other form of cancer [1]. However, the mortality rate has fallen over the years, probably as the result of increased public awareness and education programs leading to earlier detection and treatment [2]. There are four distinct categories of melanoma. These are, in order of decreasing frequency, superficial spreading, nodular, lentigo maligna, and acral lentiginous. We report herein a case of the rarer acral lentiginous type and aim to extract a rational approach to the management of this disease out of an enormous body of knowledge.

2. Case Presentation

A 58-year-old man presented with a 12-month history of a flat lesion that spread over the sole of his right foot and later became elevated, measuring 15–20 mm in diameter (Figure 1). Clinically, the lesion resembled acral lentiginous melanoma (ALM). Cutaneous examination was otherwise normal; no dysplastic or congenital nevi were identified. He was in otherwise good health, with no predisposing factors (family or personal history of melanoma, blond or red hair, freckling of the upper back, blistering sunburn before age 20, actinic keratosis, and blue, green, or gray eyes). There was no evidence of clinically apparent lymph node (inguinal) metastasis. The patient underwent an excisional biopsy of the suspicious lesion, including a layer of the underlying fatty tissue and the entire visible tumor, under local anesthesia. A narrow (2 mm) margin of surrounding skin was obtained and the wound was closed primarily in two layers in an orientation that was consistent with a possible subsequent wider excision. Histological findings were consistent with a diagnosis of ALM: intradermal features showing a diffuse proliferation of large atypical melanocytes along the epidermal-dermal junction which was dispersed in a lentiginous pattern with marked acanthosis
Figure 1: The lesion over the sole of patient’s right foot, measuring 15–20 mm in diameter.

Figure 2: Perform of a wide local excision of the skin and underlying subcutaneous tissues with a margin of 2 cm.

and elongation of the rete ridges. The complete pathologic report included the following: Breslow thickness: 1,6 mm, absence of ulceration, Clark level II, negative surgical margins, absence of satellitosis, and absence of regression. Following the diagnosis, the patient was subjected to a thorough diagnostic evaluation to determine the possible spread of the disease to other sites. History focused on constitutional, central nervous system, pulmonary, gastrointestinal, and soft tissue symptoms; physical examination included a detailed inspection and palpation of the skin and subcutaneous tissue to detect satellites, in-transit metastases, other primary tumors, and lymph node enlargement; chest X-ray and abdominal ultrasonography were all negative for the presence of disease. Sentinel lymph node biopsy was consequently performed. The first (sentinel) lymph node draining the tumor was identified, removed, and since micrometastases were not identified in frozen-section examination, a complete lymph node dissection was not performed. According to the American Joint Committee on Cancer (AJCC) system of TNM (tumor, node, metastasis) classification, the tumor stage was IB (T2aN0M0). A wide local excision of the skin and underlying subcutaneous tissues was performed with a margin of 2 cm (Figure 2). A split-thickness thick (>0.016 inches) skin graft was used to reconstruct the excisional defect, providing an excellent aesthetic result (Figures 3(a) and 3(b)). The donor site was the anterior surface of the right thigh, which was left to heal by secondary intention. During an 18-month followup, no local or distant recurrence was observed.

3. Discussion

The term ALM was first described by Reed as a subtype of melanoma [3]. It was so named owing to its predilection of acral areas of the body, in particular the palms, soles, and the subungual areas, and its distinct radial or “lentiginous” growth phase. Although ALM is the rarest subtype of cutaneous melanoma, it represents the most common category diagnosed on the foot [4].

Clinical management of melanoma begins with an accurate diagnosis. Clinicians should have a low threshold to perform a diagnostic biopsy on any changing lesion. In our case the decision to perform a biopsy of the suspicious lesion was based on clinical experience.

A 1–3 mm margin of normal skin is taken if the wound can be closed primarily. Wider margins should be avoided to permit accurate subsequent lymphatic mapping. If removal of the entire lesion creates too large a defect, then punch biopsy or excision of a representative segment of the lesion is recommended. Once a diagnosis of melanoma is made, the biopsy scar and any remains of the lesion need to be removed to eradicate any remaining tumor. The size of the surgical margins depends on the tumor thickness. For in situ lesions a 0.5- to 1-cm margin of normal skin is adequate for cure. Thin melanomas (≤1 mm) require a 1-cm margin to prevent local recurrence; lesions between 1,01 and 2 mm should have a margin of 1-2 cm. For lesions between 2,01 and 4 mm, a 2 cm margin is recommended. Extending the resection beyond 2 cm does not appear to decrease local recurrence rates. Melanoma of fingers and toes requires digital amputation [5, 6].

The surrounding tissue should be removed down to the superficial fascia to remove all lymphatic channels. If the deep fascia is not involved by the tumor, removing it does not affect recurrence or survival rates, so the fascia is left intact. Generally, the wounds should be closed primarily. Larger tissue defects may be closed with local rotational/advancement skin flaps or a skin graft [7].

Evidence of tumor in regional lymph nodes is a poor prognostic sign. This is accounted for in the staging system by advancing any T classification from Stage I or II to Stage III. All clinically positive lymph nodes should be removed by regional nodal dissection unless unresectable
distant metastases are present. Therapeutic lymph node dissection includes a superficial inguinal lymphadenectomy. The deep (iliac and obturator) nodes should be removed in the presence of clinical or radiographic evidence of deep node involvement or if there are more than three positive superficial nodes or when Cloquet’s node is positive [8–11].

For patients with lesions less than 0.75 mm the tumor cells are still localized in the surrounding tissue, and treatment of regional lymph nodes is not beneficial. With lesions more than 4 mm, it is highly likely that the tumor cells have already spread to the regional lymph nodes and distant sites. Removal of the lymph nodes has no effect on survival [12, 13]. In patients with intermediate-thickness tumors (0.76 to 4.0 mm) and no clinical evidence of nodal or metastatic disease the efficacy of sentinel lymph node (SLN) biopsy has been established [13–18]. By using a combination of isotope lymphatic mapping, an intraoperative hand-held gamma probe, and intraoperative injection of blue dye, the SLN can be identified in more than 95% of cases in the groin and axilla. The sentinel node(s) is (are) removed, and if micrometastases are identified in frozen-section examination, a complete lymph node dissection is performed. Recently, detailed pathologic analysis of the sentinel nodes via step sections and immunohistochemistry along with diagnosis of submicroscopic disease based on genetic changes detectable by the polymerase chain reaction, enabled detection of micrometastases that could be missed by standard techniques [19].

Authors’ Contribution

All authors contributed the same.

Acknowledgments

There are no acknowledgments to refer.

Consent

We confirm that the patient, described in the case report, has given his informed consent for the case report to be published.

References

[1] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009.
[2] D. S. Rigel and J. A. Carucci, “Malignant melanoma: prevention, early detection, and treatment in the 21st century,” CA Cancer Journal for Clinicians, vol. 50, no. 4, pp. 215–236, 2000.
[3] R. Reed, “Acral lentiginous melanoma,” in New Concepts in Surgical Pathology of the Skin, W. Hartmann and R. Reed, Eds., pp. 89–90, John Wiley & Sons, New York, NY, USA, 1976.
[4] D. A. Hudson, J. E. J. Krige, and H. Stubbings, “Plantar melanoma: results of treatment in three population groups,” Surgery, vol. 124, no. 5, pp. 877–882, 1998.
[5] “National Comprehensive Cancer Network Practice Guidelines in Oncology,” http://www.nccn.org.
[6] C. M. Balch, S.-J. Soong, T. Smith et al., “Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas,” Annals of Surgical Oncology, vol. 8, no. 2, pp. 101–108, 2001.
[7] S. Hansen, S. Mathes, and D. Young, “Skin and subcutaneous tissue,” in *Schwartz’s Principles of Surgery*, F. C. Brunicardi, D. K. Andersen, T. R. Billiar, D. L. Dunn, J. G. Hunter, and R. E. Pollock, Eds., pp. 1297–1315, McGraw-Hill, New York, NY, USA, 8th edition, 2005.
[8] D. G. Coit, “Extent of groin dissection for melanoma,” *Surgical Clinics of North America*, vol. 1, pp. 271–280, 1992.
[9] D. G. Coit and M. F. Brennan, “Extent of lymph node dissection in melanoma of the trunk or lower extremity,” *Archives of Surgery*, vol. 124, no. 2, pp. 162–166, 1989.
[10] P. Shen, A. M. Conforti, R. Essner, A. J. Cochran, R. R. Turner, and D. L. Morton, “Is the node of Cloquet the sentinel node for the iliac/obturator node group?” *Cancer Journal*, vol. 6, no. 2, pp. 93–97, 2000.
[11] T. M. D. Hughes, R. P. A’Hern, and J. M. Thomas, “Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma,” *British Journal of Surgery*, vol. 87, no. 7, pp. 892–901, 2000.
[12] M. M. Urist and S. J. Soong, “Melanoma and cutaneous malignancies,” in *Sabiston Textbook of Surgery, The Biological Basis of Modern Surgical Practice*, C. M. Townsend, R. D. Beauchamp, B. M. Evers, and K. L. Mattox, Eds., pp. 767–785, WB Saunders, Philadelphia, Pa, USA, 18th edition, 2008.
[13] J. F. Thompson and H. M. Shaw, “The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome?” *Annals of Surgical Oncology*, vol. 9, no. 8, pp. 719–722, 2002.
[14] B. M. Clary, M. S. Brady, J. J. Lewis, and D. G. Coit, “Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence,” *Current Surgery*, vol. 60, no. 1, pp. 16–20, 2003.
[15] S. Dessurault, S. J. Soong, M. I. Ross et al., “Improved staging of node-negative patients with intermediate to thick melanomas (> 1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy,” *Annals of Surgical Oncology*, vol. 8, no. 10, pp. 766–770, 2001.
[16] D. L. Morton, A. J. Cochran, J. F. Thompson et al., “Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial,” *Annals of Surgery*, vol. 242, no. 3, pp. 302–313, 2005.
[17] D. L. Morton, J. F. Thompson, A. J. Cochran et al., “Sentinel-node biopsy or nodal observation in melanoma,” *The New England Journal of Medicine*, vol. 355, no. 13, pp. 1307–1317, 2006.
[18] T. M. Johnson, V. K. Sondak, C. K. Bichakjian, and M. S. Sabel, “The role of sentinel lymph node biopsy for melanoma: evidence assessment,” *Journal of the American Academy of Dermatology*, vol. 54, no. 1, pp. 19–27, 2006.
[19] B. M. Clary, M. S. Brady, J. J. Lewis, and D. G. Coit, “Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence,” *Annals of Surgery*, vol. 233, no. 2, pp. 250–258, 2001.